- Home
- CANG vs ESPR Comparison
CANG vs ESPR Comparison
Compare CANG & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANG
- ESPR
- Stock Information
- Founded
- CANG 2010
- ESPR 2008
- Country
- CANG China
- ESPR United States
- Employees
- CANG N/A
- ESPR N/A
- Industry
- CANG Computer Software: Prepackaged Software
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CANG Technology
- ESPR Health Care
- Exchange
- CANG Nasdaq
- ESPR Nasdaq
- Market Cap
- CANG 392.4M
- ESPR 399.0M
- IPO Year
- CANG 2018
- ESPR 2013
- Fundamental
- Price
- CANG $5.05
- ESPR $2.19
- Analyst Decision
- CANG
- ESPR Buy
- Analyst Count
- CANG 0
- ESPR 5
- Target Price
- CANG N/A
- ESPR $7.30
- AVG Volume (30 Days)
- CANG 1.1M
- ESPR 8.9M
- Earning Date
- CANG 11-04-2024
- ESPR 11-07-2024
- Dividend Yield
- CANG N/A
- ESPR N/A
- EPS Growth
- CANG N/A
- ESPR N/A
- EPS
- CANG 0.19
- ESPR N/A
- Revenue
- CANG $38,020,222.00
- ESPR $295,451,000.00
- Revenue This Year
- CANG $253.48
- ESPR $186.90
- Revenue Next Year
- CANG N/A
- ESPR $31.10
- P/E Ratio
- CANG $27.17
- ESPR N/A
- Revenue Growth
- CANG N/A
- ESPR 187.12
- 52 Week Low
- CANG $0.96
- ESPR $1.58
- 52 Week High
- CANG $9.66
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CANG 53.04
- ESPR 42.08
- Support Level
- CANG $4.35
- ESPR $2.12
- Resistance Level
- CANG $9.66
- ESPR $2.54
- Average True Range (ATR)
- CANG 0.92
- ESPR 0.39
- MACD
- CANG 0.09
- ESPR -0.13
- Stochastic Oscillator
- CANG 25.56
- ESPR 16.67
About CANG Cango Inc. each representing two (2)
Cango Inc is an automotive transaction service platform in China connecting dealers, financial institutions, car buyers, and other industry participants. The services mainly consist of - automotive financing facilitation, automotive transaction facilitation, and aftermarket service facilitation. Geographically, it derives revenue from China.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.